TY - JOUR
T1 - Acid-degradable particles for protein-based vaccines
T2 - Enhanced survival rate for tumor-challenged mice using ovalbumin model
AU - Standley, Stephany M.
AU - Kwon, Young Jik
AU - Murthy, Niren
AU - Kunisawa, Jun
AU - Shastri, Nilabh
AU - Guillaudeu, Steven J.
AU - Lau, Lana
AU - Fréchet, Jean M.J.
PY - 2004
Y1 - 2004
N2 - Acid-degradable protein-loaded polymer particles show promise for antigen-based vaccines due to their ability to activate cytotoxic T lymphocytes (CTLs) in vitro. Protein loadings and cytotoxic T lymphocyte activation efficiencies have now been enhanced through novel delivery vehicle designs. In particular, the use of a more hydrophilic acid-degradable cross-linker leads to increased water dispersibility and increased protein loading efficiency for the particles. A 2.5-fold increase in protein encapsulation allows the delivery of more protein antigen to antigen presenting cells (APCs) leading to a 20-fold rise in antigen presentation levels. The mechanism by which APCs internalize these particles was explored using the phagocytosis inhibitor, cytochalasin B. In addition, preliminary in vivo experiments were conducted to investigate the ability of the protein-loaded particles to provide immunity against tumors in mice, and an enhanced survival rate over the use of protein alone was observed, indicating that this vaccine delivery strategy has great practical potential.
AB - Acid-degradable protein-loaded polymer particles show promise for antigen-based vaccines due to their ability to activate cytotoxic T lymphocytes (CTLs) in vitro. Protein loadings and cytotoxic T lymphocyte activation efficiencies have now been enhanced through novel delivery vehicle designs. In particular, the use of a more hydrophilic acid-degradable cross-linker leads to increased water dispersibility and increased protein loading efficiency for the particles. A 2.5-fold increase in protein encapsulation allows the delivery of more protein antigen to antigen presenting cells (APCs) leading to a 20-fold rise in antigen presentation levels. The mechanism by which APCs internalize these particles was explored using the phagocytosis inhibitor, cytochalasin B. In addition, preliminary in vivo experiments were conducted to investigate the ability of the protein-loaded particles to provide immunity against tumors in mice, and an enhanced survival rate over the use of protein alone was observed, indicating that this vaccine delivery strategy has great practical potential.
UR - http://www.scopus.com/inward/record.url?scp=9244220169&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9244220169&partnerID=8YFLogxK
U2 - 10.1021/bc049956f
DO - 10.1021/bc049956f
M3 - Article
C2 - 15546194
AN - SCOPUS:9244220169
SN - 1043-1802
VL - 15
SP - 1281
EP - 1288
JO - Bioconjugate Chemistry
JF - Bioconjugate Chemistry
IS - 6
ER -